Table 1

Clinical trials integrating immunotherapy into overall treatment systems

Study	NCT number	Treatment	Disease status	Results
CARTITUDE-2	NCT04133636	Cilta-cel	Cohort A: PD after 1–3 prior lines of therapy	mFU 17.1 m, ORR 95%, MRD negativity rate 100%
			Cohort B: early relapse after front-line therapy	mFU 18.0 m, ORR 100%, MRD negativity rate 93%
			Cohort C: RRMM after PI, IMiD, anti-CD38, and anti-BCMA therapy	mFU 11.3 m, ORR 95%, MRD negativity rate 70%
			Cohort D: NDMM after first-line induction therapy and ASCT	/^#
			Cohort E: HRNDMM	/^#
			Cohort F: NDMM with very good partial response or better after initiation of therapy	/^#
CARTITUDE-5	NCT04923893	VRd followed by cilta-cel vs. VRd followed by Rd	NDMM; ASCT not planned as initial therapy	Recruiting^*
CARTITUDE-6	NCT05257083	Dara-VRd followed by cilta-cel vs. Dara-VRd followed by ASCT	NDMM	Not yet recruiting^*
KarMMa-2	NCT03601078	Ide-cel	Cohort A: PD within 18 months of initial treatment with ASCT	mFU 21.5 m, ORR 83.8%, MRD negativity rate 70%
			Cohort B: PD within 18 months of initial treatment without ASCT	mFU 17.8 m, ORR 100%, MRD negativity rate 93%
			Cohort C: MM with inadequate response post ASCT during initial treatment	mFU 27.5 m, ORR 87.1%, MRD negativity rate 62.9%
KarMMa-4	NCT04196491	4 cycles of induction therapy followed by ide-cel	HRNDMM	/^#
MagnetisMM-6	NCT05623020	Elranatamab+DR vs. DRd	NDMM; ineligible for transplantation	Recruiting^*
MagnetisMM-7	NCT05317416	Elranatamab vs. lenalidomide	NDMM with MRD positivity after transplantation	Recruiting^*